

NextCell Pharma presents at the Advanced Therapies Europe conference

NextCell Pharma participates in Advanced Therapies Europe, a European conference in Portugal on advanced cell therapies. NextCell's CSO Dr. Lindsay Davies will talk about NextCell's platform technology and the internationally recognized research generated during the development of drug product ProTrans for type 1 diabetes.

NextCell Pharma was invited to present at the Advanced Therapies Europe conference, which will take place 5 – 7 September 2023 in Portugal. NextCell participates through CEO Mathias Svahn and CSO Lindsay Davies who will talk about NextCell's research with the cell therapy drug ProTrans for the treatment of type 1 diabetes.

– For NextCell, the conference is a very good arena to present data from our clinical trials and establish contacts with potential partners and licensees for our drug candidate ProTrans, says NextCell's CEO Mathias Svahn.

Link to Advanced Therapies Europe <https://advancedtherapieseuropa.phacilitate.com>

For more information about NextCell Pharma AB, please contact:

Mathias Svahn, CEO

Patrik Fagerholm, CFO

Tel: 0+46 8-735 5595

E-mail: info@nextcellpharma.com

Website: www.nextcellpharma.com

LinkedIn: <https://www.linkedin.com/company/15255207/>

Twitter: <https://twitter.com/NextCellPharma>

For information about Cellaviva, please contact:

Sofie Falk Jansson, Head of Cellaviva

Tel: 08-735 2010

E-mail: info@cellaviva.se

Website: www.cellaviva.se

Facebook: <https://www.facebook.com/cellavivasverige>

Twitter: <https://www.instagram.com/cellaviva/>

About NextCell Pharma AB

NextCell is a phase II cell therapy company with the drug candidate ProTrans for the treatment of type 1 diabetes. The focus is to take ProTrans to market approval via a Phase III study. ProTrans is in addition to diabetes, used in two clinical trials for Covid-19, in Örebro and Montreal (Canada). The company is in the processes of establishing its own GMP facility for production of ProTrans. The GMP facility is expected to be ready for production of smaller quantities of ProTrans in 2023. NextCell furthermore owns 8,5% in FamicordTX, a CAR-T start-up in oncology and 100 % of Cellaviva, Scandinavia's largest stem cell bank for family saving stem cells from umbilical cord blood and umbilical cord tissue with permission from the Swedish Health and Social Care Inspectorate (IVO).